WO1998008849A1 - Method for producing epothilones, and intermediate products obtained during the production process - Google Patents
Method for producing epothilones, and intermediate products obtained during the production process Download PDFInfo
- Publication number
- WO1998008849A1 WO1998008849A1 PCT/DE1997/000111 DE9700111W WO9808849A1 WO 1998008849 A1 WO1998008849 A1 WO 1998008849A1 DE 9700111 W DE9700111 W DE 9700111W WO 9808849 A1 WO9808849 A1 WO 9808849A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- solution
- methyl
- hydrogen
- mixture
- Prior art date
Links
- 0 C*=Cc1c[s]c(C)n1 Chemical compound C*=Cc1c[s]c(C)n1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to processes for the production of epothilones and intermediates within the process.
- Epothilone 1 (DE 41 38 042 C2) represent a new class of tubulin-stabilizing natural products with T.axol-like activity. Their cytotoxic activity against drug-resistant tumor cell lines is of enormous importance for potential use in cancer therapy [G. Höfle , N. Bedorf, H. Steinmetz, D. Schomburg, K. Gerth, H. Reichenbach Angew. Chem. 1996, 108, 1671; Appl. Chem. Int. Ed. Engl. 1996, 35, 1567; D. Schinzer "Epothiiones - New Promising Microtubule-stabilizing Natural Products with Taxol-like Biological Activity", Eur. Chem. Chron. 1996, 1, 7; D.M.
- Epothilones 1 are accessible in a convergent reaction from the three building blocks 2, 3 and 4.
- building blocks 2 and 3 are linked in a stereoselective aldol reaction.
- Esterification with fragment 4 provides the almost fully functionalized fragment 17, which is in A cyclization metathesis to deoxy-epothilone A 19 is cyclized.
- a final epoxidation finally provides 1
- the key step in the synthesis is the stereoselective aldol reaction of fragments 2 and 3 (obtainable from the commercially available heptenic acid).
- 70 is obtained % Yield exclusively the desired compound 5 with the four correctly placed asymmetry centers.
- Double stereodifferentiation obviously leads to a chiral override of the preferred Cra selectivity of the aldehyde 3, since both reactants are optically active Form are used
- ERSATZBI_ATT (RULE 26) The invention thus relates to a process for the preparation of epitholone A or B of the general formula 1
- R hydrogen (A) or a methyl group (B), a thiazole alkyl die ⁇ alcohol derivative of the formula 4th
- B benzyl, tetrahydropyranyl and / or a silyl protecting group (s) and
- R hydrogen or methyl, is esterified, the ester obtained is ring-closed by means of an open metathesis in the presence of a noble metal catalyst, optionally the hydroxyl protective groups
- REPLACEMENT BI ATT (RULE 26) are cleaved, the newly formed double bond is epoxidized and, if necessary, the hydroxyl protective groups are cleaved.
- Suitable as silyl protective groups B are generally all different trialkyl or diaryl-alkyl silyl protective groups, in particular the tert-butyl-diethyl, trimethylsilyl and diphenyl-tert-butyl-silyl groups.
- the epoxidation of the newly formed double bond is preferably carried out using peracid, e.g. B. perchloric acid, or peroxide, e.g. B. cumene hydroperoxide or dimethyldioxirane.
- peracid e.g. B. perchloric acid
- peroxide e.g. B. cumene hydroperoxide or dimethyldioxirane.
- the invention further includes deoxy-epothilones according to general formula 19a
- B benzyl, tetrahydropyranyl and / or a silyl protective group ( ⁇ ) and
- R hydrogen or methyl, and the meaning of B in the molecule can be different, and compounds of the general formula 4a
- the (S) alcohol 10 [D. Schinzer, A. Limberg, OM Böhm, Chem. Eur. J. 1996, 2, 1477] was first silylated with TBSCI, then ozonized to methyl ketone 12 and converted to the tricyclic olefin 13 in a stereoselective Horner-Wadsworth-Emmons reaction ⁇ A selective desilylation with HF in acetonitrile gives compound 14. The desilylation to 14 only works in the presence of some glass splinters; the reaction is apparently catalyzed by H2SiF6. Dess-Martin oxidation followed by a Wittig
- ERSATZB.LATT (RULE 26) Olefination generates compound 16, which in a final desilylation with TBAF in THF segment 4 yields.
- the 3 - [(terf-butyldimethylsilyl) oxy] propanal 42 is prepared starting from propane-1,3-diol 40 by first using a method of P.G. McDougal, J.G. Rico, Y. Oh, B.D. Condon, J. Org. Chem. 1986, 51, 3388-3390, is monosilylated to 3 - [(tert-butyldimethylsilyl) oxy] -1-propanol 41, which is then oxidized with DMSO / oxalyichloride to form aldehyde 42 (A. Jenmalm , W. Berts, Y. Li, K. Luthmann, I. Csöregh, U. hacksell, J. Org. Chem. 1994, 59, 1139-1148).
- the THF is then pumped off at RT (14 mm Hg / 1 h), (0.5 mm / 2 h) and the residue is dissolved in 10.5 ml of diethyl ether.
- the solution is cooled to -78 ° C. and 1,382 g (7.34 mmol, 1 equiv) aldehyde 42 are added dropwise.
- the mixture is stirred for 12 h at -78 ° C. and then allowed to warm to RT.
- the reaction mixture is mixed with 10.7 ml of 3N NaOH solution, then with 4.4 ml of 30% H2O2 solution and heated under reflux for 2 h.
- the organic phase is separated off, saturated with 15 ml of H2O and 15 ml.
- Diastereomer 1 30.04 (q), 25.73 (t), 24.64 (t), 20.03 (q), 19.25 (q), 15.99 (q), 11.67
- Diastereomer 2 30.02 (q), 25.41 (t), 25.08 (t), 20.85 (q), 20.30 (q), 18.90 (q), 11.95
- the sodium 6-hydroxyhexanoate is produced according to a regulation by Wulff, Krüger and Röhle Chem. Ber. 1971, 704, 1387-1399 made from ⁇ -caprolactone.
- reaction solution is then reduced to a quarter in vacuo. It is diluted with 130 ml of sat. NaCI solution and adjust to pH 4-5 with 1 M KHS04 solution. It is extracted with diethyl ether. The combined organic phases are dried over MgSO4 and the solvent is distilled off on a rotary evaporator. This gives 2.01 g (8.17 mmol) of 6 - [(terr-rutvlriimethvlsilvhoxvl-hexanoic acid, corresponding to a yield of 90%.
- 2H26 ⁇ 3Si, FG 246.42 g / mol
- aqueous phase is extracted with ether, the combined organic phases are dried over MgSO 4 and the solvent is distilled off on a rotary evaporator.
- Connection 22a is established analogously. From 2.03 g (8.0 mmol) 21a, 1.56 g (5.84 mmol, 73%) are obtained.
- Connection 23a is established analogously. From 748 mg (2.80 mmol) 22a. you get
- Connection 3a is established analogously. 199 mg (1.42 mmol, 71%) 3a are obtained from 284 mg (2.00 mmol) 23a.
- Ozone in 02 is passed at -78 ° C through a solution of 1, 610 g (4.67 mmol) H in 200 ml absolute dichloromethane (dry ice / acetone cooling bath). If starting compound H can no longer be detected by thin layer chromatography, 3.89 g (14.83 mmol) of triphenylphosphine are added and the cooling bath is removed. The reaction mixture is allowed to slowly come to room temperature and the solvent is distilled off in vacuo. Flash chromatography of the residue through a silica gel column with pentane / Et2 ⁇ (50: 1) gives 1.135 g (3.27 mmol, 70%) 12.
- ERSATZB.LATT Diethyl (2-methylthiazol-4-yl) methane phosphonate
- ERSATZB.LATT (RULE 26) (S, 4 ⁇ -4- [3- (fert-Butyldimethylsiiyloxy) -2-methyl-hexa-1,5-dienyl] -2-methyl-thiazole 16
- B stands for benzyl, p-methoxybenzyl, tetrahydropyranyl or a silyl protective group; e.g. trialkyl or diaryl alkyl silyl protective groups, in particular tert.-butyl-dimethyl, trimethylsilyl and diphenyl-tert.-butyl- silyl groups
- Connection 5a is made analogously. From 238 mg (1.70 mmol) 3a, 386 mg (1.09 mmol, 64%) 5a are obtained.
- Connection 6a is established analogously. 96 mg (0.270 mmol) 5a gives 77 mg (0.246 mmol, 91%) ⁇ a.
- Pentane: diethyl ether 30: 1 purified. 462 mg (0.719 mmol, 96%) of the trisilylated product 7 are obtained as a colorless oil.
- Connection 7a is established analogously. From 204 mg (0.650 mmol) 6a 423 mg (0.644 mmol, 99%) are obtained.
- Connection 8a is established analogously. From 152 mg (0.232 mmol) 7a, 101 mg (0.186 mmol, 80%) 8a are obtained.
- REPLACEMENT BI ATT (RULE 26)
- General data: C29H58 ⁇ sSi2, FG 542.94 g / mol, compound 2a is prepared analogously. From 320 mg (0.590 mmol) ⁇ a one obtains 273 mg (0.490 mmol, 83%) Sa
- ERSATZB.LATT (RULE 26) (4S, 7H, 8S, 9S, 16S, 13Z) -4,8-di-fert-butyldim ⁇ thylsilyloxy-5 ⁇ 5,7,9-t ⁇ tra-methyl-16- [(£) -1-methyl-2- ( 2-methylthiazol-4-yl) vinyl] -1-oxa-cyclohexadec-13-ene-2,6-dione 18 and
- the invention also relates to stereoisomers of the compounds according to the claims, as are usually obtained during synthesis.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10511141A JP2001500851A (en) | 1996-08-30 | 1997-01-15 | Process for producing epothilone and intermediate products obtained during the process |
AU21493/97A AU716610B2 (en) | 1996-08-30 | 1997-01-15 | Method for producing epothilones, and intermediate products obtained during the production process |
NZ334821A NZ334821A (en) | 1996-08-30 | 1997-01-15 | Method for producing epothilones |
EP97914077A EP0923583A1 (en) | 1996-08-30 | 1997-01-15 | Method for producing epothilones, and intermediate products obtained during the production process |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19636343A DE19636343C1 (en) | 1996-08-30 | 1996-08-30 | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
DE19645361A DE19645361A1 (en) | 1996-08-30 | 1996-10-28 | Production of epothilone compounds with taxol-like activity |
DE19645361.5 | 1996-10-28 | ||
DE19645362A DE19645362A1 (en) | 1996-10-28 | 1996-10-28 | Production of epothilone compounds with taxol-like activity |
DE19636343.8 | 1996-10-28 | ||
DE19645362.3 | 1996-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998008849A1 true WO1998008849A1 (en) | 1998-03-05 |
Family
ID=27216622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/000111 WO1998008849A1 (en) | 1996-08-30 | 1997-01-15 | Method for producing epothilones, and intermediate products obtained during the production process |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0923583A1 (en) |
JP (1) | JP2001500851A (en) |
AU (1) | AU716610B2 (en) |
NZ (1) | NZ334821A (en) |
WO (1) | WO1998008849A1 (en) |
Cited By (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
WO1999059985A1 (en) * | 1998-05-18 | 1999-11-25 | Novartis Ag | Intermediates for the synthesis of epothilones and methods for their preparation |
WO1999065913A2 (en) * | 1998-06-18 | 1999-12-23 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone minor constituents |
WO1999067253A2 (en) * | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
EP0977563A1 (en) * | 1996-12-03 | 2000-02-09 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6316630B1 (en) | 1996-12-03 | 2001-11-13 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
WO2002072858A2 (en) * | 2001-02-27 | 2002-09-19 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Degradation of epothilones and ethynyl substituted epothilones |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
WO2003078411A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
US7001916B1 (en) | 1999-02-11 | 2006-02-21 | Schering, Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7091226B2 (en) | 1998-02-25 | 2006-08-15 | Novartis Ag | Cancer treatment with epothilones |
US7101702B2 (en) | 1998-02-19 | 2006-09-05 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7172884B2 (en) | 2002-09-23 | 2007-02-06 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
EP2030618A2 (en) | 2002-01-14 | 2009-03-04 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
EP2065368A1 (en) | 2004-04-07 | 2009-06-03 | Novartis Ag | Inhibitors of IAP |
WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP2266607A2 (en) | 1999-10-01 | 2010-12-29 | Immunogen, Inc. | Immunoconjugates for treating cancer |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
EP2314297A1 (en) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
EP2371822A1 (en) | 2006-03-14 | 2011-10-05 | Novartis AG | Heterobicyclic carboxamides as inhibitors for kinases |
WO2012004299A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Tetrahydro-pyrido-pyrimidine derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
CN102633792A (en) * | 2011-02-15 | 2012-08-15 | 天津尚德药缘科技有限公司 | Method for preparing epothilone D and B |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2013001445A1 (en) | 2011-06-27 | 2013-01-03 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013093849A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
CN103232464A (en) * | 2013-03-29 | 2013-08-07 | 陈星秀 | Paclitaxel-like compounds, and preparation method thereof and application thereof in anticancer mediciens |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
WO2013171642A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171641A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171640A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171639A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2013188763A1 (en) | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014102630A1 (en) | 2012-11-26 | 2014-07-03 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
WO2014184778A1 (en) | 2013-05-17 | 2014-11-20 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
WO2014198645A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
WO2015010641A1 (en) | 2013-07-24 | 2015-01-29 | Novartis Ag | Substituted quinazolin-4-one derivatives |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015042078A2 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015054669A1 (en) | 2013-10-11 | 2015-04-16 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2015153498A1 (en) | 2014-03-31 | 2015-10-08 | Epitherapeutics, Aps | Inhibitors of histone demethylases |
US9221801B2 (en) | 2013-02-27 | 2015-12-29 | Epitherapeutics Aps | Inhibitors of histone demethylases |
WO2016033169A1 (en) | 2014-08-27 | 2016-03-03 | Epitherapeutics Aps | Compounds and methods for inhibiting histone demethylases |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
EP3312164A1 (en) | 2014-03-28 | 2018-04-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
WO2018098269A2 (en) | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018237262A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
US10189787B2 (en) | 2012-10-02 | 2019-01-29 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
US10426753B2 (en) | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
WO2019212356A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B .V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
WO2019212357A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
WO2020089310A1 (en) | 2018-10-31 | 2020-05-07 | Bio Even | Flavin adenine dinucleotide (fad) for use in the prevention and/or treatment of cancer |
WO2020092385A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
WO2020256544A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click release speed and yield |
WO2020256546A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023158305A1 (en) | 2022-02-15 | 2023-08-24 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010121A1 (en) * | 1991-11-19 | 1993-05-27 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents |
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
-
1997
- 1997-01-15 AU AU21493/97A patent/AU716610B2/en not_active Ceased
- 1997-01-15 NZ NZ334821A patent/NZ334821A/en not_active IP Right Cessation
- 1997-01-15 WO PCT/DE1997/000111 patent/WO1998008849A1/en not_active Application Discontinuation
- 1997-01-15 JP JP10511141A patent/JP2001500851A/en active Pending
- 1997-01-15 EP EP97914077A patent/EP0923583A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010121A1 (en) * | 1991-11-19 | 1993-05-27 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilones, process for preparing the same and their use as medicaments and as plant protecting agents |
WO1997019086A1 (en) * | 1995-11-17 | 1997-05-29 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone derivatives, preparation and use |
Non-Patent Citations (14)
Title |
---|
BALOG,A. ET AL.: "Total Synthesis of (-)-Epothilone A", ANGEW.CHEM.INT.ED.ENGL., vol. 35, no. 23/24, January 1997 (1997-01-01), WEINHEIM, pages 2801 - 2803, XP002035359 * |
BERTINATO,P. ET AL.: "Studies toward the Synthesis of Epothilone A: Stereocontrolled Assembly of the Acyl Region and Models for Macrocyclisation", J.ORG.CHEM., vol. 61, no. 23, 1996, WASHINGTON, pages 8000 - 8001, XP002035362 * |
BLECHERT,S. ET AL.: "Synthesis of (-)-Streptenol A,(1-)-Streptenol B, C and D", LIEBIGS ANN.CHEM., December 1996 (1996-12-01), WEINHEIM, pages 2135 - 2140, XP002035675 * |
BOLLAG,M.D. ET AL.: "Epoththilones, a New Class of Microtubule-stabilizing Agents with A Taxol-like Mechanism of Action", CANCER RES., vol. 55, 1 June 1995 (1995-06-01), BALTIMORE, pages 2325 - 2333, XP002035371 * |
GERTH,K. ET AL: "Epothilones A and B: Antifungal and Cytotoxic Compounds from Sorangium cellulosum (Myxobacteria)", J.ANTIBIOT., vol. 49, no. 6, June 1996 (1996-06-01), pages 560 - 563, XP002035370 * |
GRUBBS,R.H. ET AL.: "Ring-Closing Metathesis and Related Processes in Organic Synthesis", ACC.CHEM.RES., vol. 28, 1995, pages 446 - 452, XP002035670 * |
KELLER-SCHIERLEIN,W. ET AL: "(3S,8E)-1,3-Dihydroxy-8-decen-5-on, ein Stoffwechselprodukt von Stryptomyces fimbriatus", HELV.CHIM.ACTA., vol. 4, 1983, BASEL, pages 1253 - 1261, XP002035672 * |
MENG,D, ET AL: "Studies toward a Syntesis of Epothilone A: Use of Hydropyran Templates for the Management of Acyclic Stereochemical Relationships", J.ORG.CHEM., vol. 61, no. 23, 1996, WASHINGTON, pages 7998 - 7999, XP002035361 * |
MENG,D. ET AL.: "Remote Effects in Macrolide Formation through Ring-Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners", J.AM.CHEM.SOC., vol. 119, no. 11, 1997, WASHINGTON, pages 2733 - 2734, XP002035373 * |
MEYERS,A.I. ET AL., J.ORG.CHEM., vol. 38, 1973, WASHINGTON, pages 2136 - 2143, XP002035671 * |
NERDEL,F. ET AL.: "Hepten-(6)-Säuren und Bicyclo[3.3.1]- bzw. -[3.2.0]heptanone-(6)", CHEM.BER., vol. 100, 1967, WEINHEIM, pages 720 - 735, XP002035673 * |
NICOLAOU,K.C.ET AL.: "An Approach to Epothilones Based on Olefin Methathesis", ANGEW.CHEM.INT.ED.ENGL., vol. 35, no. 20, November 1996 (1996-11-01), WEINHEIM, pages 2399 - 2401, XP002035372 * |
TAYLOR,R.E. ET AL.: "Towards the Synthesis of Epothilone A : Enantioselective Preparation of the Thiazole Sidechain and Macrocyclic Ring Closure", TETRAHEDRON LETT., vol. 38, no. 12, 1997, OXFORD, pages 2061 - 2064, XP002035674 * |
YANG,Z. ET AL.: "Total synthesis of Epothilone A : The Olefine Metathesis Approach", ANGEW.CHEM.INT.ED.ENGL., vol. 36, no. 1/2, 1997, WEINHEIM, pages 166 - 168, XP002035364 * |
Cited By (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6831076B2 (en) | 1995-11-17 | 2004-12-14 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6613912B2 (en) | 1995-11-17 | 2003-09-02 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
EP1367057A1 (en) * | 1996-11-18 | 2003-12-03 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilones C, E and F |
WO1998022461A1 (en) * | 1996-11-18 | 1998-05-28 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
US7846952B2 (en) | 1996-11-18 | 2010-12-07 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
US8076490B2 (en) | 1996-11-18 | 2011-12-13 | Helmholtz-Zentrum Fuer Infektionsforschung Gmbh | Epothilones C, D, E, and F, preparation and compositions |
US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6828340B2 (en) | 1996-12-03 | 2004-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563A4 (en) * | 1996-12-03 | 2001-04-25 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP1386922A3 (en) * | 1996-12-03 | 2004-04-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereof, analogues and uses thereof |
USRE41990E1 (en) | 1996-12-03 | 2010-12-07 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6284781B1 (en) | 1996-12-03 | 2001-09-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
EP0977563A1 (en) * | 1996-12-03 | 2000-02-09 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6603023B2 (en) | 1996-12-03 | 2003-08-05 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6300355B1 (en) | 1996-12-03 | 2001-10-09 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6369234B1 (en) | 1996-12-03 | 2002-04-09 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6316630B1 (en) | 1996-12-03 | 2001-11-13 | Sloan Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6656961B2 (en) | 1996-12-03 | 2003-12-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6723854B2 (en) | 1996-12-03 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
USRE41893E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US8536327B2 (en) | 1997-07-08 | 2013-09-17 | Bristol-Myers Squibb Company | Epothilone derivatives |
US8921542B2 (en) | 1997-07-08 | 2014-12-30 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41895E1 (en) | 1997-07-08 | 2010-10-26 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE43003E1 (en) | 1997-07-08 | 2011-12-06 | Bristol-Myers Squibb Company | Epothilone derivatives |
USRE41911E1 (en) | 1997-07-08 | 2010-11-02 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7241755B2 (en) | 1997-07-08 | 2007-07-10 | Bristol-Myers Squibb Company | Epothilone derivatives |
US7125899B2 (en) | 1997-07-08 | 2006-10-24 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1847540A1 (en) * | 1997-08-09 | 2007-10-24 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique |
WO1999007692A3 (en) * | 1997-08-09 | 1999-05-14 | Schering Ag | New epothilone derivatives, method for producing same and their pharmaceutical use |
US7407975B2 (en) | 1997-08-09 | 2008-08-05 | Bayer Schering Pharma Ag | Epothilone derivatives, method for producing same and their pharmaceutical use |
WO1999007692A2 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US7101702B2 (en) | 1998-02-19 | 2006-09-05 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
US7091226B2 (en) | 1998-02-25 | 2006-08-15 | Novartis Ag | Cancer treatment with epothilones |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6831090B2 (en) | 1998-04-21 | 2004-12-14 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6350878B1 (en) | 1998-05-18 | 2002-02-26 | Novartis Ag | Intermediates for the synthesis of epothilones and methods for their preparation |
WO1999059985A1 (en) * | 1998-05-18 | 1999-11-25 | Novartis Ag | Intermediates for the synthesis of epothilones and methods for their preparation |
EP1275648A1 (en) * | 1998-06-18 | 2003-01-15 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone minor constituents |
WO1999065913A2 (en) * | 1998-06-18 | 1999-12-23 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Epothilone minor constituents |
US6624310B1 (en) | 1998-06-18 | 2003-09-23 | Gesellschaft Fuer Biotechnologische Forschung, Mbh (Gbf) | Epothilone minor constituents |
US7235669B2 (en) | 1998-06-18 | 2007-06-26 | Helmholtz-Zentrum Fur Infektionsforschung, Gmbh | Epothilone side components |
WO1999065913A3 (en) * | 1998-06-18 | 2000-04-20 | Biotechnolog Forschung Gmbh | Epothilone minor constituents |
US7579366B2 (en) | 1998-06-22 | 2009-08-25 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
WO1999067253A2 (en) * | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
WO1999067253A3 (en) * | 1998-06-22 | 2000-04-20 | Novartis Ag | Desmethyl epothilones |
US6531497B1 (en) | 1998-06-22 | 2003-03-11 | The Scripps Research Institute | Epothilone derivatives and their synthesis and use |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
WO2000031247A2 (en) | 1998-11-20 | 2000-06-02 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6858411B1 (en) | 1998-11-20 | 2005-02-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US6921650B1 (en) | 1998-11-20 | 2005-07-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7067286B2 (en) | 1998-11-20 | 2006-06-27 | Kosan Biosciences, Inc. | Cystobacterineae host cells containing heterologous PKS genes for the synthesis of polykedtides |
US7129071B1 (en) | 1998-11-20 | 2006-10-31 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6583290B1 (en) | 1998-11-20 | 2003-06-24 | Kosam Biosciences, Inc. | 14-methyl epothilone derivatives |
US7732186B2 (en) | 1998-11-20 | 2010-06-08 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US7402421B2 (en) | 1998-11-20 | 2008-07-22 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US7244594B2 (en) | 1998-12-23 | 2007-07-17 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US7145018B2 (en) | 1999-02-05 | 2006-12-05 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US6958401B2 (en) | 1999-02-05 | 2005-10-25 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US7001916B1 (en) | 1999-02-11 | 2006-02-21 | Schering, Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US7700621B2 (en) | 1999-04-30 | 2010-04-20 | Bayer Schering Pharma Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
EP2266607A2 (en) | 1999-10-01 | 2010-12-29 | Immunogen, Inc. | Immunoconjugates for treating cancer |
EP2289549A2 (en) | 1999-10-01 | 2011-03-02 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
USRE39356E1 (en) * | 2000-03-20 | 2006-10-17 | Bristol-Myers Squibb Co. | Process for the preparation of epothilone analogs |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
US7153879B2 (en) | 2000-08-16 | 2006-12-26 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US6689802B2 (en) | 2000-08-16 | 2004-02-10 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
USRE39251E1 (en) * | 2000-08-16 | 2006-08-29 | Bristol-Myers Squibb Co. | Polymorphs of an epothilone analog |
US6982276B2 (en) | 2000-08-16 | 2006-01-03 | Bristol-Myers Squibb Company | Polymorphs of an epothilone analog |
US8632788B2 (en) | 2001-01-25 | 2014-01-21 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
US6576651B2 (en) | 2001-01-25 | 2003-06-10 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6670384B2 (en) | 2001-01-25 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
US7022330B2 (en) | 2001-01-25 | 2006-04-04 | Bristol-Myers Squibb Company | Parenteral formulation for epothilone analogs |
USRE40387E1 (en) * | 2001-01-25 | 2008-06-17 | Bristol-Myers Squibb Company | Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones |
US6727276B2 (en) | 2001-02-20 | 2004-04-27 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
USRE41393E1 (en) | 2001-02-20 | 2010-06-22 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
US6686380B2 (en) | 2001-02-20 | 2004-02-03 | Bristol-Myers Squibb Company | Treatment of refractory tumors using epothilone derivatives |
WO2002072858A3 (en) * | 2001-02-27 | 2002-12-19 | Biotechnolog Forschung Gmbh | Degradation of epothilones and ethynyl substituted epothilones |
WO2002072858A2 (en) * | 2001-02-27 | 2002-09-19 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Degradation of epothilones and ethynyl substituted epothilones |
EP1564217A2 (en) * | 2001-02-27 | 2005-08-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Process for the production of epothilones |
EP1564217A3 (en) * | 2001-02-27 | 2005-08-31 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Process for the production of epothilones |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US8569347B2 (en) | 2001-03-14 | 2013-10-29 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US8598215B2 (en) | 2001-03-14 | 2013-12-03 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US6800653B2 (en) | 2001-06-01 | 2004-10-05 | Bristol-Myers Squibb Compnay | Epothilone derivatives |
EP2210643A2 (en) | 2001-07-19 | 2010-07-28 | Novartis AG | Combinations comprising epothilones and pharmaceutical uses thereof |
EP2030618A2 (en) | 2002-01-14 | 2009-03-04 | Novartis AG | Combinations comprising epothilones and anti-metabolites |
WO2003078411A1 (en) | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
US6936628B2 (en) | 2002-04-04 | 2005-08-30 | Bristol-Myers Squibb Company | Oral administration of epothilones |
US7053069B2 (en) | 2002-05-15 | 2006-05-30 | Bristol-Myers Squibb Company | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US7172884B2 (en) | 2002-09-23 | 2007-02-06 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
US7241899B2 (en) | 2002-09-23 | 2007-07-10 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
US7767432B2 (en) | 2002-09-23 | 2010-08-03 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and x-ray crystal structures of epothilone B |
USRE42191E1 (en) | 2002-09-23 | 2011-03-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B |
EP2065368A1 (en) | 2004-04-07 | 2009-06-03 | Novartis Ag | Inhibitors of IAP |
EP2253614A1 (en) | 2004-04-07 | 2010-11-24 | Novartis AG | Inhibitors of IAP |
EP2270008A1 (en) | 2005-05-20 | 2011-01-05 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors |
EP2292617A1 (en) | 2005-05-20 | 2011-03-09 | Novartis AG | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |
WO2007038459A2 (en) | 2005-09-27 | 2007-04-05 | Novartis Ag | Carboxyamine compounds and their use in the treatment of hdac dependent diseases |
EP2022498A2 (en) | 2005-11-21 | 2009-02-11 | Novartis AG | Neuroendocrine tumour treatment |
EP2275103A2 (en) | 2005-11-21 | 2011-01-19 | Novartis AG | mTOR inhibitors in the treatment of endocrine tumors |
EP2371822A1 (en) | 2006-03-14 | 2011-10-05 | Novartis AG | Heterobicyclic carboxamides as inhibitors for kinases |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
EP2314297A1 (en) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
EP2272511A1 (en) | 2006-05-09 | 2011-01-12 | Novartis AG | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
EP2491923A2 (en) | 2007-02-15 | 2012-08-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
EP2359818A1 (en) | 2007-02-15 | 2011-08-24 | Novartis AG | Combination of LBH589 with HSP 90 inhibitors for treating cancer |
WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
EP2628726A1 (en) | 2008-03-26 | 2013-08-21 | Novartis AG | Hydroxamate-based inhibitors of deacetylases b |
WO2010083617A1 (en) | 2009-01-21 | 2010-07-29 | Oncalis Ag | Pyrazolopyrimidines as protein kinase inhibitors |
WO2010088335A1 (en) | 2009-01-29 | 2010-08-05 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010149755A1 (en) | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
WO2011015652A1 (en) | 2009-08-07 | 2011-02-10 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
WO2011018454A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2011023677A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
WO2011054828A1 (en) | 2009-11-04 | 2011-05-12 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
WO2011070030A1 (en) | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
WO2011076786A1 (en) | 2009-12-22 | 2011-06-30 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
WO2012004299A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Tetrahydro-pyrido-pyrimidine derivatives |
WO2012035078A1 (en) | 2010-09-16 | 2012-03-22 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012066095A1 (en) | 2010-11-19 | 2012-05-24 | Novartis Ag | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
CN102633792A (en) * | 2011-02-15 | 2012-08-15 | 天津尚德药缘科技有限公司 | Method for preparing epothilone D and B |
WO2012149413A1 (en) | 2011-04-28 | 2012-11-01 | Novartis Ag | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012168884A1 (en) | 2011-06-09 | 2012-12-13 | Novartis Ag | Heterocyclic sulfonamide derivatives |
EP3228325A1 (en) | 2011-06-10 | 2017-10-11 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
WO2013001445A1 (en) | 2011-06-27 | 2013-01-03 | Novartis Ag | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
WO2013093849A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
WO2013093850A1 (en) | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
WO2013096060A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096051A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096059A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
WO2013096049A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EP3272754A1 (en) | 2012-01-26 | 2018-01-24 | Novartis AG | Imidazopyrrolidinone compounds |
EP3064502A1 (en) | 2012-01-26 | 2016-09-07 | Novartis AG | Imidazopyrrolidinone compounds |
WO2013171642A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171641A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171640A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013171639A1 (en) | 2012-05-15 | 2013-11-21 | Novartis Ag | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 |
WO2013175417A1 (en) | 2012-05-24 | 2013-11-28 | Novartis Ag | Pyrrolopyrrolidinone compounds |
WO2013188763A1 (en) | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
US10189787B2 (en) | 2012-10-02 | 2019-01-29 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US10221139B2 (en) | 2012-10-02 | 2019-03-05 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
WO2014102630A1 (en) | 2012-11-26 | 2014-07-03 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
US9650339B2 (en) | 2013-02-27 | 2017-05-16 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US9221801B2 (en) | 2013-02-27 | 2015-12-29 | Epitherapeutics Aps | Inhibitors of histone demethylases |
CN103232464A (en) * | 2013-03-29 | 2013-08-07 | 陈星秀 | Paclitaxel-like compounds, and preparation method thereof and application thereof in anticancer mediciens |
CN103232464B (en) * | 2013-03-29 | 2015-08-19 | 四川农业大学 | Taxoid compound and preparation thereof and the application in cancer therapy drug |
WO2014184778A1 (en) | 2013-05-17 | 2014-11-20 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
WO2014198645A1 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
WO2015010641A1 (en) | 2013-07-24 | 2015-01-29 | Novartis Ag | Substituted quinazolin-4-one derivatives |
WO2015022662A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022664A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015022663A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Compounds and compositions as inhibitors of mek |
WO2015042077A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015042078A2 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015054659A1 (en) | 2013-10-11 | 2015-04-16 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
US11434278B2 (en) | 2013-10-11 | 2022-09-06 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
WO2015054669A1 (en) | 2013-10-11 | 2015-04-16 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
US10316080B2 (en) | 2013-10-11 | 2019-06-11 | Asana Biosciences, Llc | Protein-polymer-drug conjugates |
EP3312164A1 (en) | 2014-03-28 | 2018-04-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
EP3327006A1 (en) | 2014-03-28 | 2018-05-30 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
WO2015153498A1 (en) | 2014-03-31 | 2015-10-08 | Epitherapeutics, Aps | Inhibitors of histone demethylases |
US10426753B2 (en) | 2014-04-03 | 2019-10-01 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
WO2016033169A1 (en) | 2014-08-27 | 2016-03-03 | Epitherapeutics Aps | Compounds and methods for inhibiting histone demethylases |
US9802941B2 (en) | 2014-08-27 | 2017-10-31 | Gilead Sciences, Inc. | Compounds and methods for inhibiting histone demethylases |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2018004338A1 (en) | 2016-06-27 | 2018-01-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
WO2018098269A2 (en) | 2016-11-23 | 2018-05-31 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2018237262A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
WO2019143874A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2019212356A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B .V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
WO2019212357A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
WO2020092385A1 (en) | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
WO2020089310A1 (en) | 2018-10-31 | 2020-05-07 | Bio Even | Flavin adenine dinucleotide (fad) for use in the prevention and/or treatment of cancer |
WO2020256546A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
WO2020256544A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click release speed and yield |
WO2023031445A2 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023158305A1 (en) | 2022-02-15 | 2023-08-24 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
Also Published As
Publication number | Publication date |
---|---|
EP0923583A1 (en) | 1999-06-23 |
AU2149397A (en) | 1998-03-19 |
AU716610B2 (en) | 2000-03-02 |
NZ334821A (en) | 2000-12-22 |
JP2001500851A (en) | 2001-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998008849A1 (en) | Method for producing epothilones, and intermediate products obtained during the production process | |
US6043372A (en) | Intermediates in the process for preparing epothilones | |
US6441186B1 (en) | Epothilone analogs | |
US7407975B2 (en) | Epothilone derivatives, method for producing same and their pharmaceutical use | |
DE19645362A1 (en) | Production of epothilone compounds with taxol-like activity | |
DE19645361A1 (en) | Production of epothilone compounds with taxol-like activity | |
Martin et al. | How stable are epoxides? A novel synthesis of epothilone B | |
DE19636343C1 (en) | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds | |
WO2000000485A1 (en) | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use | |
US20060040990A1 (en) | Epothilone derivatives, process for their production, and their pharmaceutical use | |
JP2005500974A (en) | Synthesis of epothilones and related analogues | |
Yokokawa et al. | Total synthesis of (−)-hennoxazole A | |
Cases et al. | Synthetic studies towards furanocembrane diterpenes. A total synthesis of bis-deoxylophotoxin | |
Chakraborty et al. | Total synthesis of (+)-crocacin C | |
Shin et al. | Synthesis and biological evaluation of (−)-dictyostatin and stereoisomers | |
WO2000049020A2 (en) | Novel epothilon derivatives, method for the production thereof and their pharmaceutical application | |
US20090036691A1 (en) | Analogs of dicodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | |
US4237055A (en) | Synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid | |
DE60213884T2 (en) | Process for the preparation of epothilones | |
Takikawa et al. | Triterpenoid total synthesis. Part 4. 1 Synthesis of (±)-hippospongic acid A, a triterpene isolated from the marine sponge Hippospongia sp. | |
JP4170628B2 (en) | New production method of butenolides | |
DE19735575A1 (en) | New di:hydroxy-butanal or -pentene derivatives | |
DE19830060A1 (en) | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis | |
DE19923001A1 (en) | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis | |
DE10331004A1 (en) | Process for the preparation of C1-C15 fragments of epothilones and their derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997914077 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 511141 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09254018 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 334821 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997914077 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997914077 Country of ref document: EP |